• Wondering whether CRISPR Therapeutics at around US$51.76 is offering fair value or a potential mispricing opportunity? This article breaks down the numbers for you in plain terms.
• The stock has seen a 6.0% gain over the last week, an 11.9% decline over the past month, and a 3.7% decline year to date, while still showing a 48.4% return over the last year and 19.1% over three years, alongside a 58.0% decline over five years.
• Recent attention on CRISPR Therapeutics has focused on its position in gene editing and how investors are weighing long term potential against risks in the biotechnology space. This context helps explain why the share price has moved sharply at times as sentiment around the sector has shifted.
• On Simply Wall St's valuation framework, CRISPR Therapeutics scores a 3 out of 6. The rest of this article will compare different valuation methods before finishing with a broader way to think about what that score really means for you.

Approach 1: CRISPR Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash a business might generate in the future and discounts those amounts back to today, to arrive at an estimate of what the entire company could be worth right now.

For CRISPR Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow is a loss of about $345.4 million. Analyst estimates and Simply Wall St extrapolations then project Free Cash Flow moving to $204.5 million by 2030, with a full set of yearly projections out to 2035 expressed in the data above. All figures are in $ and are below $1b, so they are expressed in millions.

Pulling those projected cash flows together and discounting them back to today results in an estimated intrinsic value of about $189.08 per share, compared with the current share price of around $51.76. This implies an intrinsic discount of 72.6%, which points to the shares trading well below this model’s estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests CRISPR Therapeutics is undervalued by 72.6%. Track this in your watchlist or portfolio, or discover 64 more high quality undervalued stocks.

Approach 2: CRISPR Therapeutics Price vs Book

For companies that are not yet consistently profitable, price based multiples linked to earnings can be hard to use, so investors often look at asset based measures like the Price to Book, or P/B, ratio instead. Book value reflects the net assets on the balance sheet, which gives you a reference point when current earnings do not tell the full story.

What counts as a reasonable P/B ratio usually depends on expectations for future returns on those assets and the risks involved. Higher expected returns and lower perceived risk can justify a higher multiple, while more uncertainty often leads investors to prefer a lower one.

CRISPR Therapeutics currently trades on a P/B of 2.59x. That sits slightly above the Biotechs industry average P/B of about 2.25x, while the selected peer group sits much higher at 19.11x. Simply Wall St also uses a proprietary “Fair Ratio” for the preferred multiple. This estimates what a reasonable P/B might be after accounting for factors like earnings growth, risk profile, profit margins, industry and market cap.

Because the Fair Ratio incorporates these company specific inputs rather than relying only on broad peer or industry comparisons, it can give a more tailored view of whether the current 2.59x looks stretched or conservative.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose Your CRISPR Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so here is an introduction to Narratives.

A Narrative is simply your story about a company, turning your view on its products, competition, risks and opportunities into concrete numbers like future revenue, margins and an assumed fair value.

On Simply Wall St, Narratives link that story to a financial forecast and then to a fair value, so you can clearly see how your expectations flow through to what you think CRISPR Therapeutics is worth.

These Narratives are available in an easy to use format on the Community page, where millions of investors share and refine their views using the same framework.

By comparing the fair value from your Narrative to the current share price, you can decide whether the gap looks wide enough to fit your own view on buying, holding or selling.

Narratives also update automatically when new data, such as earnings or important news, flows into the platform, so your view stays current without extra effort.

For example, one CRISPR Therapeutics Narrative on the Community page might assume very conservative long term adoption of gene editing therapies, while another assumes broad adoption and higher margins. This can lead to very different fair values even though both are using the same underlying tool.

Do you think there's more to the story for CRISPR Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.